Halozyme Therapeutics HALO Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's preferred stock, par or stated value per share?
- Halozyme Therapeutics (HALO) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Halozyme Therapeutics's preferred stock, par or stated value per share changed year-over-year?
- Halozyme Therapeutics's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Halozyme Therapeutics's preferred stock, par or stated value per share?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.